UroGen Pharma Ltd.
URGN
$9.87
-$0.24-2.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 90.40M | 89.36M | 85.01M | 84.30M | 82.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 90.40M | 89.36M | 85.01M | 84.30M | 82.71M |
| Cost of Revenue | 8.88M | 8.70M | 8.61M | 8.82M | 9.36M |
| Gross Profit | 81.52M | 80.67M | 76.40M | 75.48M | 73.35M |
| SG&A Expenses | 120.05M | 110.85M | 103.66M | 96.10M | 93.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.08M | 173.10M | 164.70M | 153.53M | 148.25M |
| Operating Income | -95.68M | -83.73M | -79.69M | -69.23M | -65.54M |
| Income Before Tax | -124.04M | -111.34M | -109.65M | -100.36M | -98.32M |
| Income Tax Expenses | 2.83M | 4.04M | 3.94M | 3.95M | 3.92M |
| Earnings from Continuing Operations | -126.87 | -115.38 | -113.58 | -104.32 | -102.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.87M | -115.38M | -113.58M | -104.32M | -102.24M |
| EBIT | -95.68M | -83.73M | -79.69M | -69.23M | -65.54M |
| EBITDA | -95.35M | -83.28M | -79.12M | -68.52M | -64.73M |
| EPS Basic | -3.22 | -3.14 | -3.27 | -3.39 | -3.72 |
| Normalized Basic EPS | -1.96 | -1.89 | -1.98 | -2.05 | -2.26 |
| EPS Diluted | -3.22 | -3.14 | -3.27 | -3.39 | -3.72 |
| Normalized Diluted EPS | -1.96 | -1.89 | -1.98 | -2.05 | -2.26 |
| Average Basic Shares Outstanding | 160.33M | 149.46M | 138.65M | 125.29M | 115.19M |
| Average Diluted Shares Outstanding | 160.33M | 149.46M | 138.65M | 125.29M | 115.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |